T. Rowe Price Associates’s Aegerion Pharmaceuticals AEGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-81,600
| Closed | -$242K | – | 2591 |
|
|
2016
Q3 | $242K | Sell |
81,600
-100
| -0.1% | -$173 | ﹤0.01% | 2295 |
|
|
2016
Q2 | $122K | Buy |
81,700
+71,000
| +664% | +$162K | ﹤0.01% | 2393 |
|
|
2016
Q1 | $40K | Hold |
10,700
| – | – | ﹤0.01% | 2479 |
|
|
2015
Q4 | $108K | Sell |
10,700
-3,400
| -24% | -$40.9K | ﹤0.01% | 2409 |
|
|
2015
Q3 | $192K | Hold |
14,100
| – | – | ﹤0.01% | 2302 |
|
|
2015
Q2 | $267K | Hold |
14,100
| – | – | ﹤0.01% | 2246 |
|
|
2015
Q1 | $369K | Buy |
14,100
+3,000
| +27% | +$76.3K | ﹤0.01% | 2099 |
|
|
2014
Q4 | $232K | Sell |
11,100
-76,000
| -87% | -$1.92M | ﹤0.01% | 2293 |
|
|
2014
Q3 | $2.91M | Buy |
87,100
+3,200
| +4% | +$99.3K | ﹤0.01% | 1531 |
|
|
2014
Q2 | $2.69M | Sell |
83,900
-3,355,753
| -98% | -$125M | ﹤0.01% | 1533 |
|
|
2014
Q1 | $159M | Sell |
3,439,653
-418,547
| -11% | -$24.5M | 0.04% | 492 |
|
|
2013
Q4 | $274M | Buy |
3,858,200
+491,900
| +15% | +$37.6M | 0.06% | 356 |
|
|
2013
Q3 | $289M | Sell |
3,366,300
-193,100
| -5% | -$16.4M | 0.07% | 313 |
|
|
2013
Q2 | $225M | Buy |
+3,559,400
| New | +$189M | 0.06% | 362 |
|
T. Rowe Price Associates's AEGR Position: Q4 2016 in Review
T. Rowe Price Associates sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 81,600 shares — an estimated $242K sold.
T. Rowe Price Associates first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $289M in Q3 2013. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.
- T. Rowe Price Associates reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
- T. Rowe Price Associates sold 81,600 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $242K.
- T. Rowe Price Associates first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
- T. Rowe Price Associates's Aegerion Pharmaceuticals position peaked at $289M in Q3 2013.
- 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.
Based on T. Rowe Price Associates's 13F filing for Q4 2016, filed 14 Feb 2017.